Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs

OBJECTIVE: To review recent developments in novel injectable drug delivery mechanisms and outline the advantages and disadvantages of each. DATA SOURCES: A MEDLINE (1995-January 2000) search using the terms polyethylene glycol, liposomes, polymers, polylactic acid, and controlled release was conducted. Additional references were identified by scanning bibliographies. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for inclusion. Abstracts were included only if they were judged to add critical information not otherwise available in the medical literature. DATA SYNTHESIS: A number of systems that alter the delivery of injectable drugs have been developed in attempts to improve pharmacodynamic and pharmacokinetic properties of therapeutic agents. New drug delivery systems can be produced either through a change in formulation (e.g., continuous-release products, liposomes) or an addition to the drug molecule (e.g., pegylation). Potential advantages of new delivery mechanisms include an increased or prolonged duration of pharmacologic activity, a decrease in adverse effects, and increased patient compliance and quality of life. Injectable continuous-release systems deliver drugs in a controlled, predetermined fashion and are particularly appropriate when it is important to avoid large fluctuations in plasma drug concentrations. Encapsulating a drug within a liposome can produce a prolonged half-life and a shift of distribution toward tissues with increased capillary permeability (e.g., tumors, infected tissue). Pegylation provides a method for modification of therapeutic proteins to minimize many of the limitations (e.g., poor stability, short half-life, immunogenicity) associated with these agents. CONCLUSIONS: Pegylation of therapeutic proteins is an established process with new applications. However, not all pegylated proteins are alike, and each requires optimization on a protein-by-protein basis to derive maximum clinical benefit. The language required to describe each pegylated therapeutic protein must be more precise to accurately distinguish each protein's differential pharmacologic properties.

This article has been cited by other articles:

				M. Rafienia, H. Mirzadeh, H. Mirzadeh, H. Mobedi, and A. Jamshidi In Vitro Evaluation of Drug Solubility and Gamma Irradiation on the Release of Betamethasone under Simulated In Vivo Conditions Journal of Bioactive and Compatible Polymers, July 1, 2007; 22(4): 443 - 459. [Abstract] [PDF]

				O. Hung Drug transformation: Advances in drug delivery systems/La transformation des medicaments par de nouveaux vecteurs. Can J Anesth, November 1, 2006; 53(11): 1074 - 1077. [Full Text] [PDF]

				T. Takakura, A. Takimoto, Y. Notsu, H. Yoshida, T. Ito, H. Nagatome, M. Ohno, Y. Kobayashi, T. Yoshioka, K. Inagaki, et al. Physicochemical and Pharmacokinetic Characterization of Highly Potent Recombinant L-Methionine {gamma}-Lyase Conjugated with Polyethylene Glycol as an Antitumor Agent. Cancer Res., March 1, 2006; 66(5): 2807 - 2814. [Abstract] [Full Text] [PDF]

				H. Tsubery, M. Mironchik, M. Fridkin, and Y. Shechter Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification J. Biol. Chem., September 10, 2004; 279(37): 38118 - 38124. [Abstract] [Full Text] [PDF]

				T. Stover and M. Kester Liposomal Delivery Enhances Short-Chain Ceramide-Induced Apoptosis of Breast Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 468 - 475. [Abstract] [Full Text] [PDF]

				B. A. Kerwin, B. S. Chang, C. V. Gegg, M. Gonnelli, T. Li, and G. B. Strambini Interactions between PEG and type I soluble tumor necrosis factor receptor: Modulation by pH and by PEGylation at the N terminus Protein Sci., July 1, 2002; 11(7): 1825 - 1833. [Abstract] [Full Text] [PDF]

				B. Wlotzka, S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, C. Kaduk, P. Muhn, H. Hess-Stumpp, and S. Klussmann In vivo properties of an anti-GnRH Spiegelmer: An example of an oligonucleotide-based therapeutic substance class PNAS, June 25, 2002; 99(13): 8898 - 8902. [Abstract] [Full Text] [PDF]

				K. A. Witt, J. D. Huber, R. D. Egleton, M. J. Roberts, M. D. Bentley, L. Guo, H. Wei, H. I. Yamamura, and T. P. Davis Pharmacodynamic and Pharmacokinetic Characterization of Poly(Ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2,D-Pen5]-enkephalin (DPDPE) J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 848 - 856. [Abstract] [Full Text] [PDF]